Evidence map›Paper›PMID 42851167›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Spatiotemporal heterogeneity and dynamic evolution of microglial glucose metabolic reprogramming in Alzheimer's disease.

Yuan Chen, Fuyao Li, Junlei Zhang, Mingqing Wei, Jingnian Ni, Ting Li, Lulu Yao, Jinzhou Tian, Jing Shi

Abstract readReview
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuan ChenDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Fuyao LiBeijing University of Chinese Medicine, Beijing, China.
Junlei ZhangDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Mingqing WeiDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Jingnian NiDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Ting LiDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Lulu YaoDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Jinzhou TianDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Jing ShiDepartment of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.

Funding

Beijing University of Chinese Medicine BZY-JMZY-2022-002Clinical Research and Achievement Commercialization Capacity Improvement Pilot Project of Beijing University of Chinese MedicineDongzhimen Hospital DZMG-JBZX-25001National Natural Science Foundation of China 82074362National Natural Science Foundation of China 8240154297
6 · The paper itself

Abstract

Alzheimer's disease (AD) is accompanied by persistent disturbances in brain energy metabolism, and microglial glucose metabolic reprogramming constitutes an important link among pathological protein deposition, neuroinflammation, and impaired clearance. This review examines these metabolic changes across disease stages, brain regions, and plaque-associated microenvironments and proposes a dynamic state-composition model. In this model, microglia in different metabolic states coexist, and their relative proportions and spatial distribution change as AD progresses. In early disease or during active phagocytosis, some microglia show enhanced glycolytic and oxidative phosphorylation (OXPHOS) programs. Under persistent pathological stress, increased glucose uptake may not translate into effective energy production and can coexist with inflammation and impaired lipid metabolism. In late disease, microglia with reduced metabolic capacity and impaired phagocytosis become more prevalent. However, higher expression of OXPHOS-related genes in some microglial states associated with tau pathology does not necessarily indicate improved mitochondrial respiration. These population-level patterns do not imply that individual microglia follow a fixed sequence of metabolic changes. Longitudinal cell tracking and microglia-specific metabolic flux measurements are needed to test this model and inform interventions tailored to disease stage and microglial state.

Indexed as

Alzheimer DiseaseBrainGlucoseMicrogliaAnimalsEnergy MetabolismGlycolysisHumansMetabolic ReprogrammingOxidative PhosphorylationGlucoseAlzheimer's diseaseglucose metabolismglycolysisimmunometabolismmetabolic reprogrammingmicrogliaoxidative phosphorylationspatial heterogeneity

Identifiers

PMID42851167
PMCPMC13650595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.